Country
Clinical Trials in Guinea-Bissau
Studies with at least one site in Guinea-Bissau. Open a trial for its sites in Guinea-Bissau, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 5Tuberculosis (TB), Tuberculosis Infection, Latent
Burden of Tuberculosis Among Pregnant and Postpartum Women in Guinea-Bissau
This study aims to address critical diagnostic and data gaps in tuberculosis (TB) care among pregnant and postpartum women in Guinea-Bissau, a high-burden, resource-limited setting.
- Conditions
- Tuberculosis (TB), Tuberculosis Infection, Latent, Pregnancy, Tuberculosis Diagnosis
- Trial name
- TIPP (NCT07419568)
- Testing
- Enhanced protocol
- Where
- Guinea-Bissau
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Tuberculosis
Increased Tuberculosis Case Detection - DiOpTB
As estimated by the WHO 10.6 million new Tuberculosis (TB) cases were identified in 2022- while more than three million went undetected and untreated.
- Trial name
- DiOpTB (NCT06437184)
- Testing
- ODP
- Where
- 2 sites in Ethiopia, Guinea-Bissau
- Volunteers
- 1,584 people
- Sponsor
- Aarhus University Hospital
Measles Vaccine, Hospital Admission
Measles Vaccination at Health System Contacts
In addition to protecting against measles infection, measles vaccine (MV) strengthens the individual's ability to combat infections in general - MV has beneficial non-specific effects (NSE) lowering the risk of death and…
- Conditions
- Measles Vaccine, Hospital Admission, Mortality, Non-specific (Heterologous) Effects of Vaccines
- Trial name
- NCT04220671
- Testing
- measles vaccine, Saline
- Where
- Guinea-Bissau
- Volunteers
- 5,400 people
- Sponsor
- Bandim Health Project
Infant Morbidity, Infant Mortality
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections.
- Conditions
- Infant Morbidity, Infant Mortality, Non-Specific Effects of Vaccines, BCG
- Trial name
- BCG2-DTP3 (NCT07005726)
- Testing
- BCG Vaccine
- Where
- Guinea-Bissau
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Vaccine Preventable Disease, Measles
Measles and BCG Vaccines for Mother and Child
In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other…
- Conditions
- Vaccine Preventable Disease, Measles, Mother-Infant Interaction, BCG Vaccination Reaction
- Trial name
- MATVAC (NCT04899765)
- Testing
- BCG vaccine, Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Completed, with results posted
All –Poliovirus Vaccine, Oral, COVID
OPV as Potential Protection Against COVID-19
Since the 1960s, studies have shown that oral polio vaccine (OPV) may have beneficial non-specific effects, reducing morbidity and mortality from other infections than polio.
- Conditions
- Poliovirus Vaccine, Oral, COVID, Mortality, Morbidity
- Trial name
- NCT04445428
- Testing
- oral polio vaccine + information, Information
- Where
- Guinea-Bissau
- Volunteers
- 3,729 people
- Sponsor
- Bandim Health Project
Aids, Cdc Group I
HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Treatment: Immunization with peptide-mix and adjuvant. The vaccine should induce cellular immunity against HIV-1. Target group: Untreated healthy individuals with chronic HIV-1 infection.
- Trial name
- HIV-BIS (NCT01141205)
- Testing
- AFO-18, Saline
- Where
- 2 sites in Guinea-Bissau
- Volunteers
- 18 people
- Sponsor
- Statens Serum Institut